Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission-Reference-Cited by-同舟云学术

Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remission

Published:2015-01-30 Issue:3 Volume:90 Page:242-249
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Erba Harry P.¹

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine; University of Alabama at Birmingham (UAB) and UAB Comprehensive Cancer Center; Birmingham Alabama

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23902/fullpdf

Reference66 articles.

1. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia;Shtivelman;Nature,1985

2. The molecular genetics of Philadelphia chromosome-positive leukemias;Kurzrock;N Engl J Med,1988

3. Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization;Tkachuk;Science,1990

4. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

5. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib;Deininger;Blood,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dasatinib dose management for the treatment of chronic myeloid leukemia;Cancer;2018-01-25

2. Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes;Oncotarget;2017-04-06

3. Bcr-abl regulates Stat5 through Shp2, the interferon consensus sequence binding protein (Icsbp/Irf8), growth arrest specific 2 (Gas2) and calpain;Oncotarget;2016-10-19

4. Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib;Leukemia & Lymphoma;2016-10-12

5. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia;Leukemia & Lymphoma;2016-08-10